Exhibit 10.1 PRODUCT DEVELOPMENT AGREEMENT This Agreement is dated as of May 5, 2014, BETWEEN: TRIDENT BRANDS INCORPORATED, a company incorporated under the laws of Nevada, having its principal offices located at 3rd Floor Olde Town Marina, Sandyport,...Product Development Agreement • May 14th, 2014 • Trident Brands Inc • Metal mining
PRODUCT DEVELOPMENT AGREEMENT BY AND BETWEEN SHARKNINJA EUROPE LTD. AND JS GLOBAL TRADING HK LIMITED Dated as of July 29, 2023Product Development Agreement • March 1st, 2024 • SharkNinja, Inc. • Household appliances • New York
This PRODUCT DEVELOPMENT AGREEMENT (this “Agreement”), dated as of July 29, 2023, and effective as of July 31, 2023 (the “Effective Date”), between SharkNinja Europe Ltd., a private limited company incorporated under the laws of England and Wales (“SharkNinja”), and JS Global Trading HK Limited, a private company limited by shares incorporated in Hong Kong (“JS Global”). “Party” or “Parties” means SharkNinja or JS Global, individually or collectively, as the case may be.
Exhibit 10.2 PRODUCT DEVELOPMENT AGREEMENT This agreement (the "Agreement") is entered into as of June ___, 1998 by and between UTMC MICROELECTRONIC SYSTEMS INC., a Delaware corporation, with offices located at 4350 Centennial Boulevard, Colorado...Product Development Agreement • September 25th, 1998 • Braintech Inc/Bc • Colorado
EXHIBIT 10.3 TOProduct Development Agreement • August 26th, 1997 • Icos Corp / De • Pharmaceutical preparations • New York
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • April 7th, 2023 • Growth for Good Acquisition Corp • Blank checks
Zero Nox, Inc, a company incorporated under the law of the State of California, with a principal office at 1343 S. Main Street, Porterville, CA 93257, U.S.A (“ZeroNox” or “Developer”);
EXHIBIT 10.36 PRODUCT DEVELOPMENT AGREEMENT This Product Development Agreement is made and entered into by and between Toshiba Corporation, a Japanese corporation with a principal place of business at 1-1, Shibaura 1-chome, Minato-ku, Tokyo 105-8001,...Product Development Agreement • August 16th, 2000 • Sandisk Corp • Computer storage devices • California
PRODUCT DEVELOPMENT AGREEMENT PDA-001Product Development Agreement • August 23rd, 2007 • Scivanta Medical Corp • Wholesale-medical, dental & hospital equipment & supplies • New York
This Agreement made and entered into between Scivanta Medical Corporation, with its principal office at 215 Morris Avenue, Spring Lake, New Jersey 07762 (“CUSTOMER”) and Sparton Medical Systems, a business group of Sparton Electronics Florida, Inc., a Florida Corporation, with an office at P. O. Box 788, 5612 Johnson Lake Road, DeLeon Springs, Florida 32130 (“SMS”).
MASTER FOUNDRY PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • January 11th, 2024 • Concord Acquisition Corp III • Semiconductors & related devices
This Master Foundry Product Development Agreement (“Agreement”) is entered into and is effective as of July 31, 2020 (“Effective Date”), by and between Samsung Electronics Co., Ltd., acting through its Foundry Division, having its principal place of business at 1, Samsung-ro, Giheung-gu, Yongin-si, Gyeonggi-do, 17113, Republic of Korea, on the one part (hereinafter referred to as “Samsung”); and GCT Semiconductor, Inc., a company existing under the laws of the State of Delaware, USA, having its principal place of business at 2121 Ringwood Avenue San Jose, CA 95131 and GCT Research, Inc., a company existing under the laws of the Republic of Korea, having its registered office at Construction Financial Building 11F, 15, Boramae-ro 5-gil, Dongjak-gu, Seoul (07071), Korea (hereinafter collectively referred to as “Customer”).
ADDENDUM TO PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • August 12th, 2014 • Lifelogger Technologies Corp • Services-computer processing & data preparation
THIS ADDENDUM TO PRODUCT DEVELOPMENT AGREEMENT (the “Addendum”) is made effective as of the June 1, 2014 by and between Matrico Holdings, Ltd., a company located in Hong Kong (the “Company”) and Lifelogger Technologies Corp., a Nevada corporation (“Contractor”); collectively referred to as the “Parties”.
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • April 6th, 2005 • Accentia Biopharmaceuticals Inc • Pharmaceutical preparations • North Carolina
THIS PRODUCT DEVELOPMENT AGREEMENT is made and entered into this 24th day of January, 2003 (the “Effective Date”) between Respirics, Inc., a Delaware corporation having an address at 6008 Triangle Drive, Suite 101, Raleigh, NC 27617 (hereinafter referred to as “Respirics”), and TEAMM Pharmaceuticals, a Delaware corporation and a wholly owned subsidiary of Accentia, Inc., a Florida corporation, having a primary address at 3000 Aerial Center Parkway, Suite 110, Morrisville, North Carolina 27560 (“TEAMM”).
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • March 13th, 2009 • CPC of America Inc • Surgical & medical instruments & apparatus • Nevada
FIRST AMENDMENT TO PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • July 21st, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO PRODUCT DEVELOPMENT AGREEMENT (“Amendment”), dated as of April 2, 2013 (“Amendment Effective Date”), is by and between (1) Scilex Pharmaceuticals, LLC, a company organized under the laws of the State of Delaware, with offices located at 1608 Walnut Street, Philadelphia, Pennsylvania, 92618 USA (“Scilex”), and (2) Oishi Koseido Co., Ltd., a company formed in accordance with and by virtue of the laws of Japan, having its registered office at 1-933, Honmachi, Tosu, Saga, 841-0037 Japan (“Oishi”), together with ITOCHU CHEMICAL FRONTIER Corporation, a company formed in accordance with and by virtue of the laws of Japan, having its registered office at 5-1 Kita-Aoyama 2-Chome-Minato-Ku Tokyo, Japan (“Itochu,” Oishi and Itochu are collectively “Developers”), and amends the Product Development Agreement by and between Scilex and Developers dated May 11, 2011 (“Original Agreement”). Scilex and Developers may herein after individually be referred as a “Party” or collectiv
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • August 29th, 2008 • American Home Food Products, Inc. • Dairy products • New York
This PRODUCT DEVELOPMENT AGREEMENT (this “Agreement”) is made and entered into as of the 14th day of August, 2007 by and between by Artisanal Cheese, LLC, a New York limited liability company (the “Company”), and Artisanal Fromagerie & Bistro, LLC, a New York limited liability company, and 35 West 64th Restaurant Associates, L.P., a New York limited partnership (each an “SM Restaurant,” and, together, the “SM Restaurants”).
FOURTH AMENDMENT TO PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • July 21st, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances)
THIS FOURTH AMENDMENT TO PRODUCT DEVELOPMENT AGREEMENT (this “Amendment”) is dated as of December 13, 2019 (the “Amendment Effective Date”), by and among (1) Scilex Pharmaceuticals Inc., a company formed in accordance with and by virtue of the laws of the State of Delaware, having a principal place of business at 960 San Antonio Road, Suite 100, Palo Alto, CA 94303, USA (“Scilex”), (2) Oishi Koseido Co., Ltd., a company formed in accordance with and by virtue of the laws of Japan, having a principal place of business at 1-933, Honmachi, Tosu, Saga, 841-0037 Japan (“Oishi”), and (3) ITOCHU CHEMICAL FRONTIER Corporation, a company formed in accordance with and by virtue of the laws of Japan, having a principal place of business at 5-1, Kita-Aoyama 2-Chome, Minato-Ku, Tokyo 107-0061, Japan (“Itochu”). Oishi and Itochu are collectively the “Developers”.
AMENDMENT NO. 2 TO OEM PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • February 7th, 2007 • Aspect Medical Systems Inc • Electromedical & electrotherapeutic apparatus
This AMENDMENT NO. 2 (“Amendment No. 2”) is made this 5th day of February, 2007, by and between Aspect Medical Systems, Inc., a Delaware corporation (“AMS”), and Boston Scientific Corporation, a Delaware corporation (“BSC”), and amends that certain OEM PRODUCT DEVELOPMENT AGREEMENT, dated as of August 7, 2002, among AMS and BSC (the “Agreement”), as amended by that certain Amendment No. 1 to OEM PRODUCT DEVELOPMENT AGREEMENT, dated as of January 31, 2005, among AMS and BSC (“Amendment No. 1”). Capitalized terms used herein but not otherwise defined herein shall have the meaning ascribed to them in the Agreement.
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this...Product Development Agreement • July 21st, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT (this “Amendment”) is dated as of February 20, 2017 (the “Amendment Effective Date”), by and between (1) Scilex Pharmaceuticals, Inc., a company formed in accordance with and by virtue of the laws of the State of Delaware, having a principal place of business at 301 Lindenwood Drive, Suite 300, Malvern, Pennsylvania 19355, USA (“Scilex”), (2) Oishi Koseido Co., Ltd., a company formed in accordance with and by virtue of the laws of Japan, having a principal place of business at 1-933, Honmachi, Tosu, Saga, 841-0037 Japan (“Oishi”), and (3) ITOCHU CHEMICAL FRONTIER Corporation, a company formed in accordance with and by virtue of the laws of Japan, having a principal place of business at 5-1, Kita-Aoyama 2-Chome, Minato-Ku, Tokyo 107-0061, Japan (“Itochu”). Oishi and Itochu are collectively the “Developers”.
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • August 14th, 2012
, hereinafter called "Client", and Piton Engineering, with principal offices at 5312 Seashore Dr. Suite A, Newport Beach, CA hereinafter called "Piton".
PRODUCT DEVELOPMENT AGREEMENT BETWEEN COREPHARMA LLC AND KING PHARMACEUTICALS, INC. and KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. Note: Certain material has been redacted from this document and filed separately with the SEC pursuant to a...Product Development Agreement • August 7th, 2008 • King Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS PRODUCT DEVELOPMENT AGREEMENT (“Agreement”) is made on June 18, 2008 (the “Effective Date”) by and between COREPHARMA LLC, a limited liability company, incorporated under the laws of New Jersey (“Core”), and KING PHARMACEUTICALS, INC., a corporation incorporated under the laws of Tennessee (“KPI”), and KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC., a Delaware corporation and wholly owned subsidiary of KPI (“King R&D”, and together with KPI, “King”).
Product Development AgreementProduct Development Agreement • August 30th, 2016
To best allocate IIU’s resources, and to ensure the development process is successful and efficient, it is critical to have buy-in and support from the program and their leadership.
SECOND AMENDED AND RESTATED PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • November 8th, 2006 • Sandisk Corp • Computer storage devices
This SECOND AMENDED AND RESTATED PRODUCT DEVELOPMENT AGREEMENT, dated as of July 7, 2006, is made and entered into by and between Toshiba Corporation, a Japanese corporation with a principal place of business at 1-1, Shibaura 1-chome, Minato-ku, Tokyo 105-8001, Japan (“Toshiba”), and SanDisk Corporation, a Delaware corporation with a principal place of business at 601 McCarthy Boulevard, Milpitas, CA 95035, U. S. A. (“SanDisk,” and collectively with Toshiba, the “Parties”).
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • June 20th, 2023 • Growth for Good Acquisition Corp • Motor vehicle parts & accessories
Zero Nox, Inc, a company incorporated under the law of the State of California, with a principal office at 1343 S. Main Street, Porterville, CA 93257, U.S.A (“Developer”);
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • May 12th, 2023 • Growth for Good Acquisition Corp • Motor vehicle parts & accessories
Zero Nox, Inc, a company incorporated under the law of the State of California, with a principal office at 1343 S. Main Street, Porterville, CA 93257, U.S.A (“Developer”);
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • August 12th, 2014 • Lifelogger Technologies Corp • Services-computer processing & data preparation • Florida
THIS PRODUCT DEVELOPMENT AGREEMENT (the “Agreement”) is made effective as of January 7, 2014 by and between Matrico Holdings, Ltd., a Belize corporation located at Suite 701, Tung Hip Commercial Building, No. 244-248 Des Voeux Road Central, Hong Kong (the “Company”), and Lifelogger Technologies Corp., a Nevada corporation located at 11380 Prosperity Farms Road, #221E, Palm Beach Gardens, Florida 33410 (“Contractor”). For purposes hereof, the Company and Contractor may collectively be referred to as the “Parties.”
Product Development Agreement for EbalanceProduct Development Agreement • January 16th, 2018 • Cell MedX Corp. • Retail-miscellaneous retail • British Columbia
This Development Agreement (the “Agreement”) is entered into and effective as of October 16, 2017 (the “Effective Date”) by and between Western Robotics and CELL MEDX, hereinafter the “Parties”.
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • February 9th, 2023 • Cardiovascular Systems Inc • Surgical & medical instruments & apparatus • Delaware
This Product Development Agreement (this “Agreement”), effective as of January 29, 2021 (the “Effective Date”), is made by and between Cardiovascular Systems, Inc., a Delaware corporation with its principal place of business at 1225 Old Highway 8 NW, Saint Paul, Minnesota 55112 (“CSI”), and Chansu Vascular Technologies, LLC, a Delaware limited liability company, with its principal place of business at 715 North Pastoria Avenue, Sunnyvale, CA, 94085 (“CVT” and, together with CSI, the “Parties” and each a “Party”).
SCIVANTA MEDICAL CORPORATION PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • July 3rd, 2007 • Scivanta Medical Corp • Wholesale-medical, dental & hospital equipment & supplies • New York
This Product Development Agreement (this “Agreement”) is made by and between Ethox International, Inc. (“Ethox”), a New York corporation with a principal place of business at 251 Seneca Street, Buffalo, NY 14204, and Scivanta Medical Corporation (“Scivanta”) a Nevada corporation with a principal place of business at 215 Morris Avenue, Spring Lake, NJ 07762, as follows:
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • November 9th, 2018 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This Product Development Agreement (this “Agreement”) is effective July 1, 2018 (the “Effective Date”) and is between RRD International, LLC, a Delaware limited liability company with offices at 7361 Calhoun Place, Suite 510, Rockville, MD 20855 (hereinafter “RRD”) and Eiger BioPharmaceuticals, Inc., a Delaware corporation with executive offices at 2155 Park Boulevard., Palo Alto, CA 94306 (hereinafter “Eiger”). Each of RRD and Eiger is a “Party” and together they are the “Parties.” When signed by both Parties, this Agreement will set forth the terms and conditions under which RRD agrees to provide certain product development services to Eiger as set forth herein.
Product Development AgreementProduct Development Agreement • September 19th, 2012 • Digital Blue Dog, Inc. • Florida
THIS AGREEMENT is made and entered into as of ____ day of May, 2012, by and between Feed the Dog, LLC, a New Jersey limited liability company ("Feed the Dog") and Digital Blue Dog, Inc. a Florida corporation ("Digital Blue Dog").
FIFTH AMENDMENT TO PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • July 21st, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances)
This Fifth Amendment to Product Development Agreement (this “Amendment”) is dated as of April 30, 2021 (the “Amendment Effective Date”), by and among (1) Scilex Pharmaceuticals Inc., a company formed in accordance with and by virtue of the laws of the State of Delaware, having a principal place of business at 960 San Antonio Road, Suite 100, Palo Alto, CA 94303, USA (“Scilex”), (2) Oishi Koseido Co., Ltd., a company formed in accordance with and by virtue of the laws of Japan, having a principal place of business at 1-933, Honmachi, Tosu, Saga, 841-0037 Japan (“Oishi”), and (3) ITOCHU CHEMICAL FRONTIER Corporation, a company formed in accordance with and by virtue of the laws of Japan, having a principal place of business at 5-1, Kita-Aoyama 2-Chome, Minato-Ku, Tokyo 107-0061, Japan (“Itochu”). Oishi and Itochu are collectively the “Developers”.
Product Development AgreementProduct Development Agreement • January 12th, 2024 • Ainos, Inc. • Pharmaceutical preparations
The Agreement is hereby entered into by Party A and Party B for the purpose of product development (hereinafter referred to as “Project”)
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this...Product Development Agreement • July 21st, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances) • New York
This Product Development Agreement (this “Agreement”) is hereby entered into and effective as of May 11th, 2011 (the “Effective Date”) by and between Stason Pharmaceuticals, Inc. a company organized under the laws of the state of California, with offices located at 11 Morgan, Irvine, California 92618 (“Stason) on the one hand, together with Oishi Koseido Co., Ltd., a company formed in accordance with and by virtue of the laws of Japan, having its registered office at 1-933, Honmachi, Tosu, Saga, 841-0037 Japan (“Oishi”) together with ITOCHU CHEMICAL FRONTIER Corporation, a company formed in accordance with and by virtue of the laws of Japan, having its registered office at 5-1 Kita-Aoyama 2-Chome-Minato-Ku Tokyo, Japan (“Itochu”)(Oishi and Itochu are collectively the “Developers”).
A G R E E M E N T - - - - - - - - -Product Development Agreement • August 14th, 2002 • Sandisk Corp • Computer storage devices
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • February 6th, 2014 • Dipexium Pharmaceuticals, LLC • Pharmaceutical preparations • Delaware
This Product Development Agreement (this “Agreement”) is effective January 1, 2014 (the “Effective Date”) and is between RRD International, LLC, a Delaware limited liability company with offices at (hereinafter “RRD”) and Dipexium Pharmaceuticals, LLC, a Delaware limited liability company with offices at (hereinafter “Dipexium”). Each of RRD and Dipexium is a “Party” and together they are the “Parties.” When signed by both Parties, this Agreement will set forth the terms and conditions under which RRD agrees to provide certain product development services to Dipexium as set forth herein.
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this...Product Development Agreement • July 21st, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances)
THIS THIRD AMENDMENT (this “Amendment”) is dated as of August 29th, 2018 (the “Amendment Effective Date”), by and between (1) Scilex Pharmaceuticals, Inc., a company formed in accordance with and by virtue of the laws of the State of Delaware, having a principal place of business at 4955 Directors Place, San Diego, California 92121, USA (“Scilex”), (2) Oishi Koseido Co., Ltd., a company formed in accordance with and by virtue of the laws of Japan, having a principal place of business at 1-933, Honmachi, Tosu, Saga, 841-0037 Japan (“Oishi”), and (3) ITOCHU CHEMICAL FRONTIER Corporation, a company formed in accordance with and by virtue of the laws of Japan, having a principal place of business at 5-1, Kita-Aoyama 2-Chome, Minato-Ku, Tokyo 107-0061, Japan (“Itochu”). Oishi and Itochu are collectively the “Developers”.
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • October 13th, 2005 • Valcent Products Inc. • Services-business services, nec • Texas
THIS PRODUCT DEVELOPMENT AGREEMENT (“Agreement”) is made and entered into by and between MK ENTERPRISES LLC, a Nevada corporation having a place of business at 1300 Clay Street, Winfield, Louisiana 71483 (hereinafter referred to as “MK”), and VALCENT PRODUCTS, INC., an Alberta Canada corporation, having a place of business at Suite 420, 475 Howe Street, Vancouver, British Columbia, Canada (hereinafter referred to as “VPI”):
